These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8958037)

  • 1. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
    Ross P; Heron J; Cunningham D
    Eur J Cancer; 1996; 32A Suppl 5():S13-7. PubMed ID: 8958037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
    Sculpher M; Palmer MK; Heyes A
    Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Ward S; Kaltenthaler E; Cowan J; Brewer N
    Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mature results from three large controlled studies with raltitrexed ('Tomudex').
    Cunningham D
    Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
    Hale JP; Cohen DR; Maughan TS; Stephens RJ
    Br J Cancer; 2002 Jun; 86(11):1684-90. PubMed ID: 12087450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
    Young A; Topham C; Moore J; Turner J; Wardle J; Downes M; Evans V; Kay S
    Eur J Cancer Care (Engl); 1999 Sep; 8(3):154-61. PubMed ID: 10763646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
    Groener MG; van Ineveld BM; Byttebier G; van Hout BA; Rutten FF
    Anticancer Drugs; 1999 Mar; 10(3):283-8. PubMed ID: 10327033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The costs of managing advanced colorectal cancer: a broad perspective.
    Kerr DJ; O'Connor KM
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S23-6. PubMed ID: 9376634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltitrexed in colorectal cancer.
    Drug Ther Bull; 1996 Oct; 34(10):78-80. PubMed ID: 8936802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
    Cunningham D; Zalcberg JR; Rath U; Olver I; Van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
    Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
    Norum J; Balteskard L; Edna TH; Laino R; Wählby L; Rønning G
    J Chemother; 2002 Jun; 14(3):301-8. PubMed ID: 12120887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
    Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
    Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748
    [No Abstract]   [Full Text] [Related]  

  • 14. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.
    Aristides M; Chen J; Schulz M; Williamson E; Clarke S; Grant K
    Pharmacoeconomics; 2002; 20(11):775-84. PubMed ID: 12201796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future developments with 'Tomudex' (raltitrexed).
    Van Cutsem E
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S33-8. PubMed ID: 9376636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
    Kerr DJ
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Gunasekara NS; Faulds D
    Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
    Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
    Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
    Maughan TS; James RD; Kerr DJ; Ledermann JA; McArdle C; Seymour MT; Cohen D; Hopwood P; Johnston C; Stephens RJ;
    Lancet; 2002 May; 359(9317):1555-63. PubMed ID: 12047964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.